These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer's disease. Jiang Y; Gao H Phytomedicine; 2019 Feb; 54():278-290. PubMed ID: 30668379 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, evaluation and molecular modeling study of 4-N-phenylaminoquinolines for Alzheimer disease treatment. Zhu J; Wang LN; Cai R; Geng SQ; Dong YF; Liu YM Bioorg Med Chem Lett; 2019 Jun; 29(11):1325-1329. PubMed ID: 30956012 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and cholinesterase inhibition assay of liquiritigenin derivatives as anti-Alzheimer's activity. Guan L; Peng D; Zhang L; Jia J; Jiang H Bioorg Med Chem Lett; 2021 Nov; 52():128306. PubMed ID: 34371131 [TBL] [Abstract][Full Text] [Related]
7. Further SAR studies on natural template based neuroprotective molecules for the treatment of Alzheimer's disease. Singh YP; Shankar G; Jahan S; Singh G; Kumar N; Barik A; Upadhyay P; Singh L; Kamble K; Singh GK; Tiwari S; Garg P; Gupta S; Modi G Bioorg Med Chem; 2021 Sep; 46():116385. PubMed ID: 34481338 [TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases. Guo Y; Yang H; Huang Z; Tian S; Li Q; Du C; Chen T; Liu Y; Sun H; Liu Z Molecules; 2020 Jan; 25(3):. PubMed ID: 31979317 [TBL] [Abstract][Full Text] [Related]
15. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment. Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176 [TBL] [Abstract][Full Text] [Related]
16. Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease. Purgatorio R; de Candia M; Catto M; Carrieri A; Pisani L; De Palma A; Toma M; Ivanova OA; Voskressensky LG; Altomare CD Eur J Med Chem; 2019 Sep; 177():414-424. PubMed ID: 31158754 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of ferulic acid based 1,3,4-oxadiazole hybrids as multifunctional therapeutics for the treatment of Alzheimer's disease. Tripathi A; Choubey PK; Sharma P; Seth A; Saraf P; Shrivastava SK Bioorg Chem; 2020 Jan; 95():103506. PubMed ID: 31887472 [TBL] [Abstract][Full Text] [Related]
18. Search for new multi-target compounds against Alzheimer's disease among histamine H Bajda M; Łażewska D; Godyń J; Zaręba P; Kuder K; Hagenow S; Łątka K; Stawarska E; Stark H; Kieć-Kononowicz K; Malawska B Eur J Med Chem; 2020 Jan; 185():111785. PubMed ID: 31669851 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches. Pang X; Fu H; Yang S; Wang L; Liu AL; Wu S; Du GH Molecules; 2017 Jul; 22(8):. PubMed ID: 28933746 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease. Choubey PK; Tripathi A; Sharma P; Shrivastava SK Bioorg Med Chem; 2020 Nov; 28(22):115721. PubMed ID: 33007563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]